Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573052 · ClinicalTrials.gov registry record · Phase 4
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
A Phase 4 study, sponsored by VA Salt Lake City Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT01573052 is a Phase 4 study that has completed, run by VA Salt Lake City Health Care System. The registered enrollment target is 26 participants.
The verdict
NCT01573052, a Phase 4 study, has completed, sponsored by VA Salt Lake City Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence, withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and alcohol craving.
Interventions
- DRUG Gabapentin
- DRUG Chlordiazepoxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01573052
The ClinicalTrials.gov registry entry for NCT01573052 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Salt Lake City Health Care System, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gabapentin is the first listed.
NCT01573052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01573052 about?
NCT01573052 is a clinical study titled "Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal". A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention i...
What is the current status of trial NCT01573052?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2004-03. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01573052?
The interventions under investigation include: Gabapentin (DRUG), Chlordiazepoxide (DRUG).
Who is sponsoring clinical trial NCT01573052?
This trial is sponsored by VA Salt Lake City Health Care System, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.